VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation
Figure 2
Effect of VSL#3 administration in intestinal homeostasis. A
) Intestinal permeability assay after oral challenge with 4000 Da fluorescent dextran-FITC (DX-4000-FITC); area under curve (AUC) of plasma DX-4000–FITC (μg/ml). B) Fecal score. C) Microscopy inflammatory score D) Histolopathology analysis of colon samples obtained from experimental groups. Original magnification 20×, H&E staining. Colonic cytokines content: (E) TNFα, (F) TGFβ1 and (G) RANTES. Data are mean ± SE of n = 7 mice per group. * p<0.05 ApoE−/− experimental group versus naive wild type group; ** p<0.05 ApoE−/− naïve group versus ApoE−/− plus VSL#3 group; $ p<0.05 ApoE−/− naive group versus ApoE−/− plus DSS group;# p<0.05 ApoE−/− plus DSS group versus ApoE−/− plus DSS and VSL#3 group.